UY31292A1 - Imidazoles biciclicos fusionados - Google Patents

Imidazoles biciclicos fusionados

Info

Publication number
UY31292A1
UY31292A1 UY31292A UY31292A UY31292A1 UY 31292 A1 UY31292 A1 UY 31292A1 UY 31292 A UY31292 A UY 31292A UY 31292 A UY31292 A UY 31292A UY 31292 A1 UY31292 A1 UY 31292A1
Authority
UY
Uruguay
Prior art keywords
fusionated
imidazols
bicycle
pi3k
akt
Prior art date
Application number
UY31292A
Other languages
English (en)
Inventor
Vikas Gore
Sarvesh Patel
Sachin Shivatare
Sunil Chavan
Umesh Bhise
Dr Yogesh Munot
Dr Thomas Maier
Dr Thomas Baer
Dr Hemant Joshi
Dr Astrid Zimmermann
Dr Thomas Beckers
Dr Volker Gekeler
Dr Armin Zoelch
Dr Swen Holder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07118733A external-priority patent/EP2062893A1/en
Application filed filed Critical
Publication of UY31292A1 publication Critical patent/UY31292A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos de formula (I) tautomeros o estereoisomeros de éstos, o sus sales, donde el anillo B y el imidazol al que está fusionado, R4, R6, y R7 tienen los significados indicados en la descripcion y las reivindicaciones, que son inhibidores eficaces de la vía Pi3K/AKt.
UY31292A 2007-08-14 2008-08-14 Imidazoles biciclicos fusionados UY31292A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1573MU2007 2007-08-14
EP07118733A EP2062893A1 (en) 2007-10-18 2007-10-18 Fused imidazoles for cancer treatment

Publications (1)

Publication Number Publication Date
UY31292A1 true UY31292A1 (es) 2009-03-31

Family

ID=39876840

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31292A UY31292A1 (es) 2007-08-14 2008-08-14 Imidazoles biciclicos fusionados

Country Status (24)

Country Link
US (2) US8592591B2 (es)
EP (1) EP2176259B1 (es)
JP (1) JP5327652B2 (es)
KR (1) KR20100049589A (es)
CN (1) CN101835776A (es)
AR (1) AR067946A1 (es)
AT (1) ATE503757T1 (es)
AU (1) AU2008288390A1 (es)
CA (1) CA2695251C (es)
CL (1) CL2008002397A1 (es)
CR (1) CR11271A (es)
DE (1) DE602008005894D1 (es)
DO (1) DOP2010000057A (es)
EA (1) EA201000297A1 (es)
EC (1) ECSP109965A (es)
MA (1) MA31609B1 (es)
MX (1) MX2010001745A (es)
PA (1) PA8793301A1 (es)
PE (1) PE20090596A1 (es)
SV (1) SV2010003482A (es)
TN (1) TN2010000071A1 (es)
TW (1) TW200924761A (es)
UY (1) UY31292A1 (es)
WO (1) WO2009021990A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008050821A1 (en) * 2006-10-19 2008-05-02 Takeda Pharmaceutical Company Limited Indole compound
CN101835776A (zh) * 2007-08-14 2010-09-15 拜耳先灵医药股份有限公司 用于癌症治疗的稠合的咪唑
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US20130310362A1 (en) * 2009-02-13 2013-11-21 Bayer Pharma Aktiegesellschaft Fused pyrimidines
CA2755285C (en) 2009-03-20 2014-02-11 Yunxin Y. Bo Inhibitors of pi3 kinase
EP2426135A4 (en) 2009-04-27 2013-02-20 Shionogi & Co UREA DERIVATIVE WITH PI3K-INHIBITING EFFECT
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
WO2011051342A1 (en) 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
MX2012005162A (es) * 2009-11-02 2012-06-01 Abbott Lab Imidazopiridinas como una nueva estructura base para inhibicion de cinasa en multiples objetivos.
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2593451B1 (en) 2010-07-12 2015-08-19 Bayer Intellectual Property GmbH Substituted imidazo[1,2-a]pyrimidines and -pyridines
CN103384670B (zh) 2010-07-28 2016-05-25 拜耳知识产权有限责任公司 取代的咪唑并[1,2-b]哒嗪
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
DE102011008352A1 (de) * 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
WO2012148540A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kanase inhibitors and uses threof
WO2012137870A1 (ja) * 2011-04-06 2012-10-11 大鵬薬品工業株式会社 新規イミダゾオキサジン化合物又はその塩
DK2694510T3 (en) * 2011-04-07 2016-01-18 Bayer Ip Gmbh IMIDAZOPYRIDAZINER AS AKT kinase inhibitors
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
CN104066736B (zh) 2012-01-10 2017-03-08 拜耳知识产权有限责任公司 作为akt激酶抑制剂的取代的吡唑并嘧啶
CA2860723A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
AU2013283426B2 (en) 2012-06-26 2018-02-22 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders
NO2868660T3 (es) 2012-07-02 2018-05-26
CN104411314B (zh) 2012-07-09 2017-10-20 詹森药业有限公司 磷酸二酯酶10的抑制剂
EP2976086B1 (en) 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
GB201321732D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2016136928A1 (ja) 2015-02-27 2016-09-01 大鵬薬品工業株式会社 イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3529245A4 (en) * 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THE LATEST
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2286114T3 (es) 2000-03-31 2007-12-01 Ortho-Mcneil Pharmaceutical, Inc. Imidazopiridina fenil-substituidos.
DK1277754T3 (da) * 2000-04-27 2005-11-14 Astellas Pharma Inc Imidazopyridinderivater
ATE512957T1 (de) * 2003-04-24 2011-07-15 Merck Sharp & Dohme Hemmer der akt aktivität
ES2298798T3 (es) 2003-07-30 2008-05-16 Laboratorios S.A.L.V.A.T., S.A. Imidazopirimidinas sustituidas para la prevencion y el tratamiento del cancer.
EP1737843B1 (en) * 2004-04-09 2011-02-23 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2005290081B2 (en) * 2004-08-23 2010-12-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CN101242834A (zh) 2004-12-15 2008-08-13 默克公司 Akt活性抑制剂
RU2007147382A (ru) * 2005-05-20 2009-06-27 Эррэй Биофарма Инк. (Us) Соединения, являющиеся ингибиторами raf, и способы их применения
WO2007025090A2 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US7709468B2 (en) * 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
CN101835776A (zh) * 2007-08-14 2010-09-15 拜耳先灵医药股份有限公司 用于癌症治疗的稠合的咪唑

Also Published As

Publication number Publication date
MA31609B1 (fr) 2010-08-02
WO2009021990A1 (en) 2009-02-19
CN101835776A (zh) 2010-09-15
PA8793301A1 (es) 2009-04-23
TW200924761A (en) 2009-06-16
MX2010001745A (es) 2010-03-10
JP2010535847A (ja) 2010-11-25
SV2010003482A (es) 2010-07-06
DOP2010000057A (es) 2010-04-15
CA2695251A1 (en) 2009-02-19
TN2010000071A1 (en) 2011-09-26
CA2695251C (en) 2016-06-21
EA201000297A1 (ru) 2010-08-30
ATE503757T1 (de) 2011-04-15
DE602008005894D1 (de) 2011-05-12
CR11271A (es) 2010-05-19
EP2176259B1 (en) 2011-03-30
AR067946A1 (es) 2009-10-28
CL2008002397A1 (es) 2009-09-25
AU2008288390A1 (en) 2009-02-19
US9387204B2 (en) 2016-07-12
US20090156604A1 (en) 2009-06-18
EP2176259A1 (en) 2010-04-21
PE20090596A1 (es) 2009-06-07
ECSP109965A (es) 2010-03-31
US20140088110A1 (en) 2014-03-27
US8592591B2 (en) 2013-11-26
KR20100049589A (ko) 2010-05-12
JP5327652B2 (ja) 2013-10-30

Similar Documents

Publication Publication Date Title
UY31292A1 (es) Imidazoles biciclicos fusionados
UY31293A1 (es) Pirimidinas biciclicas fusionadas
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
SV2011003997A (es) Pirimidinas fusionadas
NI201000059A (es) Inhibidores de la cinasa c-fms.
UY34261A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-2-ciclil-etil}-1h-[1,2,4]triazol sustituidos
CR20110620A (es) Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus
RS54030B1 (en) PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
UA107784C2 (en) Inhibitor of melanin production
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
CR20140216A (es) 5,7-imidazo[1,2-c]pirimidinas sustituidas
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CO6561828A2 (es) Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5)
NI201100096A (es) Lactamas como inhibidores de beta secretasa.
CR20130306A (es) Compuestos y su uso
ECSP10010425A (es) Pirrolopirimidincarboxamidas
CR8687A (es) Nuevos imidazoles
ECSP12011678A (es) Metilpirrolopirimidincarboxamidas
UY33092A (es) Compuestos de triazol, su uso y agentes que los contienen
CR11860A (es) Derivados de dibenzotiazepina y sus usos - 424
EA201400001A1 (ru) Новые производные фталазинонпирролопиримидинкарбоксамида
CO6361935A2 (es) Inhibidores de glicógeno sintasa cinasa-3 beta que contienen derivados de 7-hidroxi-benzoimidazol-4-il-metanona
CU20100029A7 (es) Imidazoles fusionados para el tratamiento del cáncer

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171011